BiotechTube
GenBody

GenBody

San Diego, United States· Est.
genbodyamerica.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

GenBody is a private diagnostics company headquartered in San Diego, specializing in rapid tests for infectious diseases. It achieved commercial stage with its FDA EUA-authorized COVID-19 antigen test, which was selected by the NIH's Rapid Acceleration of Diagnostics (RADx) initiative for US production, indicating government validation. The company operates a direct manufacturing and distribution model, targeting distributors, testing sites, and CLIA labs with scalable packaging options. Its immediate focus is capitalizing on its COVID-19 test while navigating a post-pandemic market and potential platform expansion.

Infectious Diseases

Technology Platform

Lateral flow immunoassay for rapid antigen detection, designed for point-of-care use with anterior nasal swab sampling.

Opportunities

Leverage FDA EUA experience and manufacturing scale to develop a multiplex rapid test panel for respiratory viruses (e.g., COVID-19, Flu, RSV).
Expand into other high-need, point-of-care infectious disease diagnostics, potentially in sexually transmitted infections or tropical diseases, using the established lateral flow platform.

Risk Factors

Extreme reliance on a single COVID-19 product in a rapidly contracting market poses existential revenue risk.
The product operates under a contingent EUA, not full FDA approval, and faces intense competition from larger, more diversified diagnostics companies, leading to severe price pressure.

Competitive Landscape

GenBody competes in the crowded rapid COVID-19 antigen test market against giants like Abbott (BinaxNOW), Quidel (QuickVue), and Roche, as well as numerous other smaller companies. Competitors are advancing with combination tests and digital solutions. GenBody's differentiation is its NIH RADx validation and shallow nasal swab, but it lacks a diversified portfolio compared to established players.

More companies in Diagnostics & Precision Medicine →More companies in United States →